Work

Continuing Enasidenib Treatment for Patients with Mutant- IDH2 (m IDH2) Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) with Stable Disease May Result in Improved Survival and Responses over Time

Year: 2017

Type: article

Source: Blood

DOI: 10.1182/blood.v130.suppl_1.1299.1299

Authors: Eytan M. Stein, Richard M. Stone, Daniel A. Pollyea, Gail J. Roboz, Jessica K. Altman, Courtney D. DiNardo, Stéphane de Botton, Nora Tu, Arlene S. Swern, Alessandra Tosolini, Ira Gupta, Samuel V. Agresta, Amir T. Fathi

Institutions: Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, Harvard University, University of Colorado Anschutz, University of Colorado Denver, NewYork–Presbyterian Hospital, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, The University of Texas MD Anderson Cancer Center, Université Paris-Sud, Université Paris-Saclay, Institut Gustave Roussy, Fondation Gustave Roussy, Celgene (United States), Agios Pharmaceuticals (United States), Massachusetts General Hospital

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3124364203

FWCI: 0.362

Cites:

Cited by: 2

Related to: 20